Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cadrenal Therapeutics Inc

CVKD ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.87

▲ +0.54%

Market Cap $6.67M · Vol 5.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.67M

Micro Cap

Div Yield

N/A

EPS Growth

+20.92%

YoY

RSI (14)

37.97

Momentum

Beta

1.79

vs Market

52W High

$14.56

87.16% below

52W Low

$1.76

6.25% above

Volume

5.14K

Avg 10.87K

P/B

5.79

Price-to-book

ROE

N/A

Return on equity

Free Float

88.07%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cadrenal Therapeutics Inc (CVKD) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CVKD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-4.10%

-22.73%

-64.52%

-66.21%

YTD

-72.42%

-85.53%

-83.62%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,237,360.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-183.21% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	5.79
P/FCF	N/A
EPS Growth	+20.92%
Outstanding Shares	3.57M

Technical Indicators

50-Day SMA	$2.74
200-Day SMA	$6.29
RSI (14)	37.97
Beta	1.79
52-Week High	$14.56
52-Week Low	$1.76

Volume Today	5.14K
Avg Daily Volume (30D)	10.87K
Relative Volume	0.47x
Volatility (10D)	48.77
Volatility (30D)	68.43
Free Float	88.07%

Analyst Consensus

BUY

Current Price $1.87

Mean Target $14.00

52W Low$1.76 52W High$14.56

Current

Target

$1.76 $14.56

Current Analyst target

+648.66% upside potential · 3 analysts

Identifiers

ExchangeNasdaq

FIGIBBG019STRT39

ISINUS1276362076

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 8, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.